Nature Communications

Safety and immunogenicity of PPV-06, an active anti-IL-6 immunotherapy targeting low-grade inflammation against knee osteoarthritis: a randomized, double-blind, placebo-controlled, clinical phase 1 study

2025-11-05

Full text

DOI https://doi.org/10.1038/s41467-025-64710-6